Common questions.
Royalty financing, BioPalace, and how it all fits together.
- What is a synthetic royalty?
- What is the difference between a synthetic and traditional royalty?
- Is a 7% royalty more expensive than 25% Series B dilution?
- Will a royalty financing deal prevent acquisition?
- What is the Mallinckrodt precedent and why does it matter?
- What development stage qualifies for royalty financing?
- What IRR do royalty investors target?
- How long does a royalty financing transaction take to close?
- What is rNPV?
- When should a company NOT pursue royalty financing?
Royalty financing, explained.
What is a synthetic royalty?
A synthetic royalty is a contractual arrangement created by a company that owns a drug and its intellectual property outright. Instead of licensing the asset to a partner, the company commits a percentage of the drug's future net sales to an investor in exchange for upfront capital. The company retains full ownership of the underlying IP; only a right to a portion of future revenue is sold. Synthetic royalties are non-dilutive, carry no fixed repayment obligations, and are tied to a single asset rather than the company's enterprise-wide assets.
What is the difference between a synthetic and traditional royalty?
A traditional royalty monetization is the sale of a company's existing right to receive future milestone and royalty payments from a third-party licensing agreement; the cash flow already exists as part of a previously negotiated out-licensing partnership. A synthetic royalty is the creation of a new, bespoke revenue-sharing agreement on a drug the company owns outright; the cash flow is engineered for the financing. Traditional royalties access capital from already-partnered assets. Synthetic royalties raise capital against wholly-owned assets without entering a strategic partnership or selling equity.
Is a 7% royalty more expensive than 25% Series B dilution?
Often, no. A 25% Series B dilution permanently reduces founder and existing-shareholder ownership and persists across all future value creation, including a strategic exit. A 7% royalty with a 2.0x cap pays out only on net sales of one specific asset, terminates once the investor receives 2.0x their capital, and leaves equity fully intact. For products with strong commercial potential, royalty financing frequently delivers a lower effective cost of capital than equity dilution when analyzed across realistic peak-sales scenarios.
Will a royalty financing deal prevent acquisition?
No. Major acquisitions routinely close with royalty obligations in place: Pfizer's $11.6 billion acquisition of Biohaven and Gilead's $21 billion acquisition of Immunomedics both proceeded despite existing royalty obligations on target assets. Acquirers typically handle the royalty through purchase-price adjustments, escrow arrangements, or direct assumption. The provision to watch is the change-of-control put right, present in approximately 85% of synthetic royalty transactions, which functions similarly to a debt payoff at acquisition and must be factored into purchase-price negotiations.
What is the Mallinckrodt precedent and why does it matter?
In Mallinckrodt Pharmaceuticals' bankruptcy, a royalty sale was recharacterized as an unsecured claim rather than a true property right; the investor recovered only a fraction of claim value while the debtor continued to sell the product. Post-Mallinckrodt, royalty investors demand true-sale legal opinions, security interests in the underlying IP, and bankruptcy-remote special purpose vehicles (SPVs). By 2024, 100% of reviewed synthetic royalty transactions were secured by product assets, up from 67% in 2020. The Mallinckrodt precedent is now the structural baseline for credible royalty deals.
What development stage qualifies for royalty financing?
Royalty financing is viable for Phase III assets with positive pivotal trial data and excellent for approved or commercial products. Approved products account for 72% of all royalty transactions (2020-2024). Phase III represents 22% of synthetic transactions and 3% of traditional royalties. Phases I and II combined account for less than 3% of the market. Below Phase III, the binary regulatory risk makes the math too punishing for investors targeting mid-teens IRRs; alternative financing such as venture equity is usually more appropriate.
What IRR do royalty investors target?
Royalty investors typically target mid-teens IRRs, with individual transactions priced in the 14-18% range and complemented by cash-on-cash return targets exceeding 2.0x. Approved-product royalties price at the lower end (10-15% effective cost of capital, reflecting minimal regulatory risk and visible commercial trajectory). Phase III royalties price higher (16-20%) to compensate for binary regulatory risk. Analysis of 150+ royalty transactions (2020-2025) shows median running royalty rates of 4-6% for approved assets versus 7-10% for development-stage assets.
How long does a royalty financing transaction take to close?
A well-managed royalty financing transaction typically closes in 8 to 12 weeks from initial engagement. A representative 8-week process: Week 1 covers initial screening and NDA execution. Week 2 covers preliminary commercial and clinical diligence, culminating in a non-binding indication of interest. Week 3 covers management presentations and data room access. Weeks 4 through 6 cover full diligence (commercial, medical, IP, finance). Week 7 covers valuation finalization and term sheet drafting. Week 8 covers definitive documentation, execution, and fund transfer. Complexity and party responsiveness can extend the timeline.
What is rNPV?
rNPV (risk-adjusted Net Present Value) is the core valuation framework for royalty transactions. Investors calculate rNPV using probability-weighted discounted cash flow models that account for clinical, regulatory, and commercial uncertainties. Future royalty cash flows are adjusted for the probability of reaching each milestone (for example, the approximately 52% probability of approval at Phase III) and then discounted to present value. The investor's offer falls below the asset's calculated fair value to compensate for the risk premium they assume in providing capital today against uncertain future payments.
When should a company NOT pursue royalty financing?
Royalty financing is not the right tool when: development stage is Phase I or II (wait until Phase III data or use venture equity); capital need exceeds $1 billion (use equity or strategic partnerships); peak sales potential is under $150 million (insufficient upside for investor IRR targets); the company has a weak competitive position (revenue pressure will constrain investor returns); a strategic partner is essential for commercial capabilities; multiple near-term pivots are expected (royalties are tied to a specific asset); or the company needs operational governance involvement (royalty investors are passive financial partners).
About us.
Who runs BioPalace?
BioPalace is led by Husein Hassan, Founder and CEO, whose background spans healthcare investment banking and private equity. Julien Willard, MD MPH, serves as Head of Research and Investments and brings experience as a partner in pharma strategy and as a former diplomat. Dr. Maly Hassan, MD, serves as Chief Scientific Officer; she is a resident at Emory University. The team has structured biopharma transactions, advised on global health policy, and treated patients in the clinic.
What does BioPalace specialize in?
BioPalace specializes in the sub-$50 million tier of biotech royalty transactions, a segment that incumbent royalty platforms typically cannot serve because their fund sizes and return thresholds require $50M-plus minimum capital deployments. By conducting diligence upfront and syndicating pre-vetted opportunities to a curated private network of institutional and accredited investors, BioPalace unlocks middle-market royalty financing for both issuers and investors that fall outside the mandates of the large-cap incumbents.
Is BioPalace a fund?
No. BioPalace is a syndicate platform, not a fund. There is no pooled capital, no blind-pool fund commitment, and no required capital deployment. Accredited investors review and commit to individual deals on a deal-by-deal basis, with full transaction-level disclosure before any commitment. This structure means investors retain control over which opportunities they fund and how much capital they allocate to each one, with the diligence work conducted by BioPalace before opportunities reach the network.
How does BioPalace diligence opportunities?
Every opportunity passes BioPalace's independent diligence process across four workstreams. Clinical diligence covers trial design, biostatistics, patient-level data, PK/PD, toxicology, and key opinion leader (KOL) consultations. Commercial diligence covers market sizing, competitive landscape, pricing and payor access, and gross-to-net forecasting. Regulatory, IP, and manufacturing diligence covers global IP estate review, FDA/EMA correspondence, freedom-to-operate analysis, and manufacturing readiness. Legal diligence covers existing licensing agreements, counterparty governance, and bankruptcy-aware structuring. Only the few opportunities that survive this scrutiny are syndicated.
What is BioPalace's minimum check size?
Minimum check size is disclosed in the deal room and may vary by transaction. Investments are restricted to accredited investors as defined in Rule 501(a) of the Securities Act of 1933, and any other applicable regulations. Prospective investors can request access at biopalace.com to begin the qualification process.
How does BioPalace get paid?
Fee economics are set per transaction. On the issuer side, engagement and structuring fees are scoped against the size and complexity of the deal, and success-based compensation is paid only at closing. On the investor side, deal-specific syndication economics are disclosed in full inside the deal room before any subscription commitment. There are no blind fund-level fees and no separate platform or membership charges.
Forty-two pages of frameworks and case studies.
The full BioPalace whitepaper covers everything above in depth, with worked examples and three detailed case studies (Biohaven, PTC Therapeutics, Revolution Medicines).